Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OCUL
CUSIPN/A
Phone781-357-4000
Debt
Debt-to-Equity Ratio0.22
Current Ratio4.90
Quick Ratio4.89
Price-To-Earnings
Trailing P/E Ratio-2.82
Forward P/E Ratio-4.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.92 million
Price / Sales120.38
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book8.61
Profitability
EPS (Most Recent Fiscal Year)($2.20)
Net Income$-63,380,000.00
Net Margins-3,418.79%
Return on Equity-153.53%
Return on Assets-88.54%
Miscellaneous
Employees119
Outstanding Shares37,280,000
Market Cap$244.56
Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix Inc (NASDAQ:OCUL) released its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.02. The biopharmaceutical company had revenue of $0.34 million for the quarter. Ocular Therapeutix had a negative return on equity of 153.53% and a negative net margin of 3,418.79%. View Ocular Therapeutix's Earnings History.
When is Ocular Therapeutix's next earnings date?
What price target have analysts set for OCUL?
4 Wall Street analysts have issued 12 month price targets for Ocular Therapeutix's stock. Their forecasts range from $10.00 to $22.00. On average, they expect Ocular Therapeutix's stock price to reach $14.6667 in the next year. This suggests a possible upside of 136.6% from the stock's current price. View Analyst Ratings for Ocular Therapeutix.
What is the consensus analysts' recommendation for Ocular Therapeutix?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (7/11/2018)
- 2. HC Wainwright analysts commented, "We continue to believe that Dextenza has the potential to obtain regulatory approval in the U.S. by the end of 2018 and start generating revenue around mid-2019. The company plans to apply for a pass-through reimbursement status (C code) for Dextenza. With bundled pricing of cataract surgery, Dextenza should be priced above $480 per dose according to CMS guidelines, in our view. In the wake of this update, we reiterate our Buy rating and $10 price target." (6/21/2018)
- 3. BTIG Research analysts commented, "On Thursday, before market open, the management team of Ocular Therapeutix hosted their 4Q17 earnings call. We think the updates provided on the call were in line with expectations. The company expects to resubmit the Dextenza NDA during 1H2018, with an FDA decision likely by YE2018. Key leadership positions have also been filled including the hiring of experienced quality and regulatory personnel, which we think could further provide additional investor confidence moving forward. We reiterate our Buy rating and $9 Price Target." (3/11/2018)
- 4. Cantor Fitzgerald analysts commented, "Potential Approval before The End of The Year. After receiving feedback earlier this year, Ocular believes the complete and clear nature of the FDA’s responses removes the need for a meeting to obtain additional feedback. Currently, the company is conducting on-going manufacturing runs in order to establish and support confidence limits for particulate observed. Based on the focus on manufacturing, we anticipate a Type 2 review, consistent with a manufacturing inspection and six month review timeline." (3/8/2018)
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Dynavax Technologies (DVAX), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), Epizyme (EPZM), CytomX Therapeutics (CTMX), Amarin (AMRN), Rhythm Pharmaceuticals (RYTM), Assembly Biosciences (ASMB), ANI Pharmaceuticals Inc Common Stock (ANIP), Homology Medicines (FIXX), Inflarx (IFRX), AC Immune (ACIU), Kiniksa Pharmaceuticals (KNSA), CymaBay Therapeutics (CBAY) and Rocket Pharmaceuticals (RCKT).
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Dr. Amarpreet Sawhney, Founder & Exec. Chairman (Age 51)
- Mr. Antony Mattessich, Pres, CEO & Director (Age 51)
- Mr. Donald Notman Jr., Chief Financial Officer
- Dr. Michael H. Goldstein, Chief Medical Officer (Age 51)
- Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 56)
Has Ocular Therapeutix been receiving favorable news coverage?
Media headlines about OCUL stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ocular Therapeutix earned a news impact score of 0.19 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 44.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Ocular Therapeutix?
Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of OCUL stock can currently be purchased for approximately $6.20.
How big of a company is Ocular Therapeutix?
Ocular Therapeutix has a market capitalization of $244.56 million and generates $1.92 million in revenue each year. The biopharmaceutical company earns $-63,380,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Ocular Therapeutix employs 119 workers across the globe.
How can I contact Ocular Therapeutix?
Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]
MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
